相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil
Andre de Lima Guerra Corado et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2016)
HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor
Yu Feng et al.
JOURNAL OF IMMUNOLOGY (2011)
Targeting chemokine receptors in HIV: A status report
Shawn E. Kuhmann et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients
Maria C. Rosario et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
Jacob Lalezari et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: A meta-analysis of 4 cohorts in the US epidemic
Jean K. Lim et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
Athe M. N. Tsibris et al.
JOURNAL OF VIROLOGY (2008)
Highly potent HIV inhibition:: engineering a key anti-HIV structure from PSC-RANTES into MIP-1β/CCL4
Hubert Gaertner et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal
Jurgen Vercauteren et al.
RETROVIROLOGY (2008)
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
Robert A. Ogert et al.
VIROLOGY (2008)
Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
Rama Kondru et al.
MOLECULAR PHARMACOLOGY (2008)
Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells
W. M. Sullivan et al.
ARCHIVES OF VIROLOGY (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
W. G. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART
Cathia Soulie et al.
AIDS (2007)
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis
Julie B. Dumond et al.
AIDS (2007)
CCR5 blockade modulates inflammation and alloimmunity in primates
Carsten Schroeder et al.
JOURNAL OF IMMUNOLOGY (2007)
Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
Laetitia Comte et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
CCR5: no longer a 'good for nothing' gene - chemokine control of West Nile virus infection
Jean K. Lim et al.
TRENDS IN IMMUNOLOGY (2006)
A genetic basis for human susceptibility to West Nile virus
Michael S. Diamond et al.
TRENDS IN MICROBIOLOGY (2006)
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity
S Imamura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1 - A decade of experience
A Shet et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Negative association between the chemokine receptor CCR5-Δ32 polymorphism and rheumatoid arthritis:: a meta-analysis
S Prahalad
GENES AND IMMUNITY (2006)
The discovery of tropane-derived CCR5 receptor antagonists
DR Armour et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2006)
CC-type chemokine receptor 5-Δ32 mutation protects against primary sclerosing cholangitis
L Henckaerts et al.
INFLAMMATORY BOWEL DISEASES (2006)
Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation
IF Charo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
HIV and the chemokine system: 10 years later
P Lusso
EMBO JOURNAL (2006)
HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice
EJA van Wanrooij et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor
RS Veazey et al.
NATURE MEDICINE (2005)
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
JM Strizki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion
RS Veazey et al.
NATURE (2005)
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc
MC Rosario et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans
M Baba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults
J Lalezari et al.
AIDS (2005)
TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro
CL Tremblay et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist
K Takashima et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
The CCR5-D32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source
C Goulding et al.
GUT (2005)
Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
AJ Marozsan et al.
VIROLOGY (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis
V Pokorny et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2004)
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains
DM Shen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds
DM Shen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment
M Shu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
CW Hendrix et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis
R Eri et al.
GENES AND IMMUNITY (2004)
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-Chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro
K Maeda et al.
JOURNAL OF VIROLOGY (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
The CCR5Δ32 allele is associated with reduced liver inflammation in hepatitis C virus infection
O Wald et al.
EUROPEAN JOURNAL OF IMMUNOGENETICS (2004)
The prevalence of antiretroviral drug resistance in the United States
DD Richman et al.
AIDS (2004)
Prospects of HIV-1 entry inhibitors as novel therapeutics
TC Pierson et al.
REVIEWS IN MEDICAL VIROLOGY (2004)
The chemokine receptor, CCR5
A Mueller et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5
MM Lederman et al.
SCIENCE (2004)
HIV biological variability unveiled:: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use
I Karlsson et al.
AIDS (2003)
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection
RS Veazey et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies
SQ Liu et al.
JOURNAL OF MOLECULAR MODELING (2003)
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
PF Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The entry of entry inhibitors: A fusion of science and medicine
JP Moore et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection
FA Koning et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Toxicity of antiretroviral therapy and implications for drug development
A Carr
NATURE REVIEWS DRUG DISCOVERY (2003)
Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: A molecular modeling-guided mutagenesis study the binding pocket
LA Castonguay et al.
BIOCHEMISTRY (2003)
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle
C Blanpain et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration
RF Schwabe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Enfuvirtide
RY Chen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
Antiretroviral-drug resistance among patients recently infected with HIV
SJ Little et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Target validation of G-protein coupled receptors
A Wise et al.
DRUG DISCOVERY TODAY (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins:: Differences in primary structural requirements for RANTES, MIP-1α, and vMIP-II binding
JM Navenot et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
JM Strizki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5
K Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2001)
Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children
L Ometto et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
CP Dorn et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety
M Shiraishi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
